Navigation Links
Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Date:5/13/2009

NERVIANO, Italy, May 13 /PRNewswire/ -- The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells. This new compound is orally bioavailable, highly efficient and well tolerated in preclinical models of cancer after repeated dosing. This unique inhibitor adds another promising candidate to the pipeline of innovative cell cycle targets with different mechanisms of action in clinical development which have been discovered and developed by NMS. These include inhibitors of CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the FDA in January this year and the first patients were treated with the compound in April. NMS CDK and Aurora inhibitors are in phase I and II clinical development, respectively, and are starting to show promising activity in specific patient populations.

The clinical development path foresees application of the NMS PLK-1 inhibitor in solid and hematological indications. "I am pleased to see the second IND approval this year and I highly appreciate the consistant delivery of high quality clinical candidates by the Nerviano site" comments Dr. Francesco Colotta, VP R&D at NMS.

Nerviano Medical Sciences (NMS)

Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in Nerviano generate on average two clinical candidate molecules per year. NMS takes advantage of strategic alliances with biotechnology as well as pharmaceutical companies to secure its long term business sustainability. The Company has already finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb C
'/>"/>

SOURCE Nerviano Medical Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
3. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
4. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
5. ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoracic Surgeons
6. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
7. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
8. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
9. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
10. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
11. BioMS Medical to present at Alberta Economic Forum in Geneva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
(Date:10/1/2014)... BOSTON, MA (PRWEB) September 30, 2014 ... company, SoundConnect announces four new-hosted collaboration ... innovative bundles deliver high quality conferencing experiences for ... collaboration packages to choose from, businesses have optimized ... bundled solutions include audio only minutes ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
(Date:10/1/2014)... Sept. 30, 2014 This report ... in US$ Million by the following Product ... Enzymes. Specific end-use segments also analyzed are ... The report provides separate comprehensive analytics ... Middle East, and Latin America. Annual estimates ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... November 7, 2011 Note: numbers in square ... Boulter is available for interview. Investment fund manager ... today won a court battle with 3M over the multi-national ... The High Court in London found 3M was ...
... Angioslide, a provider of Embolic Capture ... one of Israel,s top ten most promising startups of ... Ernst & Young (E&Y) Journey 2011 conference, held in ... featuring prominent technology, healthcare and cleantech companies.   ...
... LONDON, November 7, 2011 Single vaccination effective ... Congress 2011 USA SEEK, a leading UK privately-owned ... of its Universal Flu Vaccine Phase II challenge study. The ... 2011 in Arlington, Virginia, USA. FLU-v is the ...
Cached Biology Technology:3M Forced to Pay for Breach of Obligations Over MRSA - High Court 23M Forced to Pay for Breach of Obligations Over MRSA - High Court 33M Forced to Pay for Breach of Obligations Over MRSA - High Court 4Angioslide Named One of Israel's Top Ten Most Promising Startups of 2011 2SEEK Announces Successful Phase II Challenge Study of its Universal Influenza Vaccine, FLU-v 2SEEK Announces Successful Phase II Challenge Study of its Universal Influenza Vaccine, FLU-v 3SEEK Announces Successful Phase II Challenge Study of its Universal Influenza Vaccine, FLU-v 4
(Date:9/30/2014)... Ocean Health Index rates the Earth,s oceans at ... addition, for the first time, the report assessed ... national jurisdiction (high-seas areas) all critical regions ... providing sustainable food sources. , In the third ... by scientists from UC Santa Barbara,s National Center ...
(Date:9/30/2014)... led by Clemson University associate professor Brian Powell, ... the U.S. Department of Energy,s Experimental Program to ... impact on South Carolina in the advancement of ... "Understanding the scientific and engineering needs for safely ... technologies is imperative if South Carolina is to ...
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... suggest that patients with aggressive non-Hodgkin,s lymphoma in the ... researchers say. At the ESMO Conference Lugano (ECLU) ... group headed by Prof. Hamdy Azim from Cairo University ... rather than every 3 weeks as usual, improved treatment ...
... Since earliest recorded history, and presumably beyond, humans have ... of winged creatures around them, and unfailingly ended in ... particularly similar to nature,s fliers, and today there is ... chopper and the humble bumblebee, despite similar flight patterns. ...
... your imagination run away with you may actually influence ... University has found that mental imagery--what we see with ... The research was published online June 26 by the ... imagery leads to a short-term memory trace that can ...
Cached Biology News:New treatment approach promising for lymphoma patients in the developing world 2Want to fly? Don't copy the birds and the bees 2'Mind's eye' influences visual perception 2'Mind's eye' influences visual perception 3
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
Biology Products: